PTO/SB/68 (09-06)

Approved for use through 3/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN A	BANDONED APPLICA	TION UI	NDER 37 CFR 1.14
	In re Application of		
Bring completed form to:	*		
File Information Unit, Room 2E04	Application Number		Filed
2900 Crystał Drive Arlington, VA 22202-3514	Application Number		3:7-94
Annigon, VA 22202-3314	08-209502		<u> </u>
Telephone: (703) 308-2733			Paper No. <u></u>
I hereby request access under 37 CFR 1.14(a application, which is not within the file jacke and which is identified in, or to which a bene	t of a pending Continuéd Pros	secution Ap	oplication (CPA) (37 CFR 1.53(d))
United States Patent Application Publ	ication No, pa	age,	line,
United States Patent Number 55 :	2 9 3/ 2, column	, line,	or
WIPO Pub. No,	page, line	 -	
Related Information About Acc Wrapper System (IFW) and A member of the public, acting without a p through the FIU. If the member of the public available through the Public Patent Applications web site (www.uspto.gov). Terminals that The member of the public may also be ent the appropriate fee. Such copies must be appropriate fee (37 CFR 1.19(b)). For published applications that are still pe the file contents; the pending applicat application. For unpublished applications that are still (1) If the benefit of the pending application that has: (a) issued as a patent application publication, or an Article 21(2), a member of the public originally filed; or any document in the (2) If the application is incorporated by registration, a U.S. patent application accordance with PCT Article 21(2), a originally filed.	Access to Pending Application is claimed under 35 U.S.C. 1 U.S. patent, or (b) published as international patent application as originally filed; or any document of the public nation as originally filed; or any document of the public nation as originally filed; or any document of the public nation as originally filed; or any document of the publication is claimed under 35 U.S.C. 1 U.S. patent, or (b) published as international patent application patent of the pending application of the pending application of the pending application of the pending application of the publication, or an international publication, or an international	ications i polications medication file medication file medication file medication file medication file available in the second of the application in the second of the sec	n General naintained in the IFW system , then the file is made AIR) on the USPTO internet in the Public Search Room. Dilication file upon payment of icords upon payment of the icords upon payment of the icopy of: ine file of the pending 121, or 365 in another invention registration, a U.S. in accordance with PCT is pending application as setent, a statutory invention ication publication in
Adrian			1-29.08
Signature			Date
Typed or printed r			OR PTO-USE ONLY
Registration Number, it	applicable	Approved Unit:	PAPR 2 9 (mittals)
Telephone Nun	IDEF		- OIN

This collection of information is required by 37 CFR 1.11 and 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Room 2E04, 2900 Crystal Drive, Arlington, Virginia.



US005554512A

United States Patent [19]

Lyman et al.

[11] Patent Number:

5,554,512

[45] Date of Patent:

Sep. 10, 1996

[54]	LIGANDS	FOR FLT3	RECEPTO	RS

[75] Inventors: Stewart D. Lyman, Seattle; M.

Patricia Beckmann, Poulsbo, both of

Wash.

[73] Assignee: Immunex Corporation

[21] Appl. No.: 243,545

[22] Filed: May 11, 1994

Related U.S. Application Data

[63] Continuation in part of Ser. No. 209,502, Mar. 7, 1994 abandoned, which is a continuation in part of Ser. No. 162,407, Dec. 3, 1993, abandoned, which is a continuation-in-part of Ser. No. 111,758, Aug. 25, 1993, abandoned, which is a continuation-in-part of Ser. No. 106,463, Aug. 12, 1993, abandoned, which is a continuation-in-part of Ser. No. 68,394, May 24, 1993, abandoned.

[56] References Cited

U.S. PATENT DOCUMENTS

5,185,438 2/1993 Lemischka 536/23.2

OTHER PUBLICATIONS

J. G. Flanagan et al. Cell 63:185-194, 1990.O. Rosnet et al. Oncogene 6:1641-1650, Sep. 1991.

Primary Examiner—Stephen G. Walsh Assistant Examiner—Lorraine M. Spector Attorney, Agent, or Firm—Stephen L. Malaska

[57]

ABSTRACT

Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to flt3-L as an isolated protein, the DNA encoding the flt3-L, host cells transfected with cDNAs encoding flt3-L, compositions comprising flt3-L, methods of improving gene transfer to a mammal using flt3-L, and methods of improving transplantations using flt3-L. Flt3-L finds use in treating patients with anemia, AIDS and various

21 Claims, No Drawings